

## CLAIMS

- 5 1. A pharmaceutical aqueous solution comprising levosimendan or a salt thereof as an active ingredient the pH-value of the solution being lower than 5, preferably about 4.5 or lower, and optionally a solubility enhancing agent.
2. A solution according to claim 1 the pH-value of the solution being in the range of from about 3 to about 4.2.
- 10 3. Aqueous intravenous infusion solution comprising levosimendan or a salt thereof as an active ingredient the pH-value of the solution being lower than 5, preferably about 4.5 or lower, and optionally a solubility enhancing agent.
4. A solution according to claim 3 the pH-value of the solution being in the range of from about 3 to about 4.2.
5. A solution according to claim 3 or 4, wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.
- 15 6. A pharmaceutical solution, particularly an intravenous infusion concentrate, comprising
- (a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient,
- (b) pharmaceutically acceptable organic solvent comprising ethanol,
- 20 (c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4, and optionally
- (d) a water-solubility enhancing agent.
7. A solution according to claim 6, wherein the amount of said solvent is 90 – 99.9 %, preferably 95 – 99.9 %, by weight of the solution.
- 25 8. A solution according to claim 6 or 7, wherein the amount of said organic acid is 0.005 – 2 %, preferably 0.01 – 1 %, by weight of the solution.
9. A solution according to any of claims 6 - 8, wherein pharmaceutically acceptable organic acid is a 2-hydroxy alkanoic acid.
10. A solution according to claim 9, wherein pharmaceutically acceptable organic acid is citric acid, lactic acid, tartaric acid or malic acid.
- 30 11. A solution according to claim 6, wherein the amount of the water-solubility enhancing agent is 0.1 – 5 % by weight.
12. A solution according to claim 6, wherein the water-solubility enhancing agent is polyvinylpyrrolidone.
- 35 13. A solution according to claim 6 comprising
- (a) levosimendan or a pharmaceutically acceptable salt thereof in amount of 0.01 – 1.0 % by weight,
- (b) dehydrated ethanol in amount of 95 – 99.5 % by weight,

WO 01/19334

13

PCT/F100/00761

- 173 (c) citric acid in amount of 0.03 – 0.6 % by weight, and  
(d) polyvinylpyrrolidone in amount of 0.5 – 2 % by weight.

add 141